Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Investor Pullout From India Pharma’s Research Feared A Signal For More (India)

This article was originally published in PharmAsia News

Executive Summary

Some analysts fear decisions by investors to pull out of Perlecan Pharma's drug-research effort will lead to more pullouts in India. They said that could hurt drug research initiatives in India because they would find funding sources more difficult to obtain. Sources said two investor groups are discussing cancelling involvement with Perlecan, Dr. Reddy's research arm, because they are concerned about the efficacy of the molecules it was researching. One analyst noted such a pullout has not happened before in India's pharmaceutical business and other major drug makers also have separated their research units. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts